What is driving the improved financial performance in the third quarter of 2005?

The primary driver of the improved financial performance is the strong growth of Schering-Plough's cholesterol franchise, particularly the products VYTORIN and ZETIA, which are marketed through a joint venture with Merck & Co. These products have shown significant sales growth and market share gains, leading to a substantial increase in equity income from the joint venture.

What are the main risks or challenges facing Schering-Plough based on this filing?

The company faces significant risks, including a substantial increase in special charges related to litigation reserves for investigations into marketing, sales, and pricing practices. Additionally, ongoing efforts to comply with FDA consent decrees for manufacturing facilities continue to incur costs. The company also faces competitive pressures in key product areas and potential future generic competition for established products.

How is the company managing its liquidity and financial resources?

Schering-Plough is working to improve its financial situation by repatriating previously unremitted foreign earnings under the American Jobs Creation Act, which is expected to fund U.S. operational needs. The company also has a $1.5 billion revolving credit facility available for general corporate purposes. However, significant cash outflows in financing activities, including debt repayment and dividend payments, are noted.

What is the impact of the joint venture with Merck on Schering-Plough's financial statements?

The company utilizes the equity method of accounting for the joint venture with Merck for cholesterol-lowering drugs. The results of the joint venture are reflected as 'Equity income from cholesterol joint venture' on the income statement. This income is driven by the sales performance of VYTORIN and ZETIA, and while contributing positively, the company also incurs significant related selling, general, and administrative costs that are not directly reflected in the joint venture's equity income but are part of Schering-Plough's overall cost structure.

MRK 10-Q Quarterly Report Q3 FY2005 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation reported a net income of $65 million for the third quarter of 2005, a significant increase from $26 million in the prior year period. For the nine-month period, the company swung to a net income of $143 million from a net loss of $112 million in the same period of 2004. This turnaround was largely driven by the strong performance of its cholesterol franchise, VYTORIN and ZETIA, which continue to gain market share. Despite these positive developments, the company faces ongoing challenges, including substantial litigation reserves, particularly related to investigations into marketing and pricing practices, which led to a significant increase in special charges. The company also continues to navigate complex regulatory environments and manufacturing compliance efforts. From an operational perspective, net sales increased by 15% year-over-year in the third quarter, driven by prescription pharmaceuticals and animal health segments. However, Selling, General, and Administrative expenses also rose, impacting profitability. The company's liquidity remains a focus, with efforts to repatriate foreign earnings to support U.S. operations, although this also involves tax considerations.

Key Highlights

1Net income available to common shareholders for Q3 2005 was $43 million ($0.03 per diluted share), a substantial improvement from $14 million ($0.01 per diluted share) in Q3 2004.
2Nine-month net income available to common shareholders was $78 million, a significant turnaround from a net loss of $124 million in the same period of 2004.
3Consolidated net sales increased 15% to $2.28 billion in Q3 2005 compared to $1.98 billion in Q3 2004, driven by prescription pharmaceuticals and animal health.
4Equity income from the cholesterol joint venture with Merck increased significantly to $215 million in Q3 2005 from $95 million in Q3 2004, reflecting strong sales of VYTORIN and ZETIA.
5Special charges increased significantly to $292 million for the nine months ended September 30, 2005, primarily due to an increase in litigation reserves related to investigations into marketing and pricing practices.
6Research and development expenses increased by 50% to $566 million in Q3 2005, including a $124 million charge related to the development rights for golimumab.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2005

Summary

Key Highlights

Frequently Asked Questions